Roche: have abandoned some trials due to U.S. drug pricing plans
Send a link to a friend
[July 27, 2023]
FRANKFURT (Reuters) -Roche said it had abandoned certain drug
development projects or acquisitions under consideration because of
planned price cuts in best-selling prescription medicines in the United
States.
Speaking in a media call after the release of first-half results, CEO
Thomas Schinecker said the Swiss group was not taking the lead on any
legal action against the U.S. government project under the Inflation
Reduction Act (IRA), because other large drugmakers were much more
severely affected, but its work on new drugs was impacted still.
"We have decided that we are not going to do certain trials, or that we
are not going to do a merger or acquisition or licensing (deal) because
it is becoming financially not viable," said Schinecker. He declined to
elaborate.
The comments come after some drugmakers including Merck & Co and Bristol
Myers Squibb have launched legal challenges against the U.S.
government's plan to give Medicare the power to negotiate drug prices.
[to top of second column]
|
![](../images/072723PIX/health55.jpg)
Pharmaceutical tablets and capsules are
arranged in the shape of a U.S. dollar sign on a table in this
picture illustration taken in Ljubljana August 20, 2014. REUTERS/Srdjan
Zivulovic/File Photo
![](http://archives.lincolndailynews.com/2015/May/02/images/ads/current/guzzardo_lda022609.png) Schinecker said on Thursday the
company would continue to monitor the situation.
(Reporting by Ludwig BurgerEditing by Miranda Murray and Josephine
Mason)
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |